Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 15/09/2023, Status: Authorised
Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 15/09/2023, Status: Authorised
